CMS Medicare Drug Coverage Fraud Alerts

被引:0
|
作者
Gingerich, Barbara Stover [1 ,2 ]
机构
[1] Advantage Consultants Inc, Orlando, FL 32806 USA
[2] York Coll Penn, Dept Nursing, York, PA USA
来源
关键词
drug; Medicare; prescription; marketing; fraud; prevention;
D O I
10.1177/1084822305284745
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
These proactive preventative steps seemed to herald a new approach to fraud and abuse detection. This new approach allowed the expansion of the core efforts of government agencies to other partnering groups and organizations to detect, report, investigate, and refer findings. This provides for increased monitoring from diverse fronts and increases scrutiny of the health care provider industry as a whole. From a home care and hospice prospective, it is important that we understand what prescription drug plans are allowed and not allowed to market and promote to the Medicare beneficiary. It is also important that we know the parameters of any allowable telemarketing from companies offering prescription drug plans and that we be able to assist our patients in adding their telephone numbers to the Do Not Call lists. In regard to privacy and inappropriate use of personal information, there are several telephone numbers to have available for use. They are: • Medicare Beneficiaries Contact - (800) MEDICARE or (800) 633-4227 • The Federal Trade Commission's ID Theft Hotline - (866) 653-4261 These numbers can prove useful for other concerns, not just those relating to the Medicare prescription drug benefit. It is also important that home care and hospice providers acquire an understanding of how the more basic Medicare Part D plans are structured and be able to at a minimum assist Medicare beneficiaries in contacting plans. In regard to hospice care provision and reimbursement, it is also important to realize that this new prescription drug plan is separate from and does not affect those medications included as part of the hospice patient's hospice election drug benefit. And as always, providers should understand and learn from the directions taken by CMS pertaining to one program area in that successful activities and efforts are then often replicated in other arenas. © 2006 Sage Publications.
引用
收藏
页码:408 / 409
页数:2
相关论文
共 50 条
  • [2] DRUG COVERAGE UNDER MEDICARE
    不详
    LANCET, 1969, 1 (7606): : 1149 - +
  • [3] Medicare beneficiaries and drug coverage
    Poisal, JA
    Chulis, GS
    HEALTH AFFAIRS, 2000, 19 (02) : 248 - 256
  • [4] Medicare drug coverage and moral hazard
    Pauly, MV
    HEALTH AFFAIRS, 2004, 23 (01) : 113 - 122
  • [5] CMS Considers Controversial Alzheimer Drug Coverage
    Rubin, Rita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (08): : 690 - 690
  • [6] Effects of Expanded Coverage for Chiropractic Services on Medicare Costs in a CMS Demonstration
    Stason, William B.
    Ritter, Grant A.
    Martin, Timothy
    Prottas, Jeffrey
    Tompkins, Christopher
    Shepard, Donald S.
    PLOS ONE, 2016, 11 (02):
  • [7] Drug coverage and drug purchases by medicare beneficiaries with hypertension
    Blustein, J
    HEALTH AFFAIRS, 2000, 19 (02) : 219 - 230
  • [8] Medicare fraud
    Brown, S
    NATION, 1997, 265 (05) : 6 - 7
  • [9] Medicare Fraud
    Mitka, Mike
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (18): : 1801 - 1801
  • [10] A political history of medicare and prescription drug coverage
    Oliver, TR
    Lee, PR
    Lipton, HL
    MILBANK QUARTERLY, 2004, 82 (02): : 283 - +